Clinical trials: Hemostatic Disorders
Multiple Myeloma
Effects of Exercise in Combination With Epoetin Alfa
The purpose of the study was to determine the effect of Epoetin alfa therapy (short term versus long term) with and without a home-based individualized exercise program that incorporated aerobic and strength resistance training…
- Trial name
- NCT00577096
- Testing
- Epoetin Alfa, Exercise, Autologous Peripheral Blood Stem Cell Transplantation
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- University of Arkansas
Multiple Myeloma
A Study of Daratumumab With Pomalidomide, Dexamethasone, and All-Transretinoic Acid in Patients With Multiple Myeloma
The purpose of this study is to test the safety and efficacy of the study drug daratumumab, when given together with Pomalidomide, Dexamethasone, and All-Transretinoic Acid (ATRA).
- Trial name
- NCT04700176
- Testing
- Daratumumab, Pomalidomide, All-trans retinoic acid
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Hackensack Meridian Health
Graft Versus Host Disease, Leukemia
Treatment of Single or Double Umbilical Cord Trans + Graft-versus-host Disease (GVHD) Prophylaxis w/ Tacrolimus & Mycophenolate Mofetil
RATIONALE: Giving chemotherapy and total-body irradiation before a donor umbilical cord blood transplant helps stop the growth of cancer and abnormal cells and helps stop the patient's immune system from rejecting the donor's…
- Conditions
- Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00608517
- Testing
- anti-thymocyte globulin, cyclophosphamide, fludarabine phosphate
- Where
- 4 sites in United States
- Volunteers
- 6 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Multiple Myeloma
Study to Evaluate the Combination of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy
In this study, investigators will evaluate the activity of bendamustine, bortezomib and dexamethasone (BBD). This regimen combines 3 agents with high activity in multiple myeloma, with different mechanisms of action and…
- Trial name
- NCT01056276
- Testing
- Bendamustine, Bortezomib, Dexamethasone
- Where
- 13 sites in United States
- Volunteers
- 59 people
- Sponsor
- SCRI Development Innovations, LLC
Multiple Myeloma
Once-weekly Versus Twice-weekly Carfilzomib in Combination With Dexamethasone in Adults With Relapsed and Refractory Multiple Myeloma
The purpose of the study is to compare the progression-free survival (PFS) of once-weekly carfilzomib dosing in combination with dexamethasone to twice-weekly carfilzomib dosing in combination with dexamethasone in adults with…
- Trial name
- ARROW (NCT02412878)
- Testing
- Carfilzomib, Dexamethasone
- Where
- 140 sites in United States, Australia and 18 more
- Volunteers
- 478 people
- Sponsor
- Amgen
Multiple Myeloma
A Study to Investigate the Efficacy and Safety of Two Doses of GSK2857916 in Participants With Multiple Myeloma Who Have Failed Prior Treatment With an Anti-CD38 Antibody
Multiple myeloma (MM) is an incurable malignancy and accounts for 1 percentage (%) of all cancers and for 10% of all hematologic malignancies.
- Trial name
- NCT03525678
- Testing
- Belantamab mafodotin frozen liquid, Belantamab mafodotin lyophilized powder
- Where
- 59 sites in United States, Australia and 6 more
- Volunteers
- 221 people
- Sponsor
- GlaxoSmithKline
Relapsed/Refractory Multiple Myeloma
NINLARO Capsules Drug Use-Results Survey (All-Case Surveillance) "Relapsed/Refractory Multiple Myeloma"
The purpose of this study is to evaluate the safety of NINLARO in participants with relapsed/refractory multiple myeloma in daily clinical practice.
- Trial name
- NCT03169361
- Testing
- Ixazomib
- Where
- Japan
- Volunteers
- 774 people
- Sponsor
- Takeda
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell Transplant
This phase II trial studies pentostatin and donor lymphocyte infusion in preventing graft rejection in patients who have undergone donor stem cell transplant.
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- Trial name
- NCT00096161
- Testing
- Cyclosporine, Mycophenolate Mofetil, Pentostatin
- Where
- 5 sites in United States, Italy
- Volunteers
- 36 people
- Sponsor
- Fred Hutchinson Cancer Center
Leukemia, Lymphoma
Planned Donor Lymphocyte Infusion (DLI) After Allogeneic Stem Cell Transplantation (SCT)
The goal of this clinical research study is to learn what dose of a kind of immune cell called T-lymphocytes (T-cells) given as a donor infusion about 8-9 weeks after a stem cell transplant has the best results.
- Conditions
- Leukemia, Lymphoma, Myeloma, Myeloproliferative Diseases
- Trial name
- NCT01518153
- Testing
- Fludarabine, Melphalan, Alemtuzumab
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- M.D. Anderson Cancer Center
Refractory Multiple Myeloma
Dinaciclib in Treating Patients With Relapsed or Refractory Multiple Myeloma
This phase II trial is studying how well giving dinaciclib works in treating patients with relapsed or refractory multiple myeloma.
- Trial name
- NCT01096342
- Testing
- dinaciclib, laboratory biomarker analysis
- Where
- 6 sites in United States, Singapore
- Volunteers
- 16 people
- Sponsor
- National Cancer Institute (NCI)
Multiple Myeloma
Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma
This study will evaluate the efficacy and safety of belantamab mafodotin in combination with pomalidomide and dexamethasone (Arm A) compared with that of combination of pomalidomide, bortezomib and dexamethasone (Arm B) in…
- Trial name
- DREAMM 8 (NCT04484623)
- Testing
- Belantamab mafodotin, Pomalidomide, Dexamethasone
- Where
- 122 sites in United States, Australia and 16 more
- Volunteers
- 302 people
- Sponsor
- GlaxoSmithKline
Multiple Myeloma
High-Dose Weekly Carfilzomib Plus Cyclophosphamide and Dexamethasone in the Treatment of Relapsed Multiple Myeloma
The purpose of this study is to find out what effects carfilzomib has on relapsed multiple myeloma when administered in combination with cyclophosphamide and dexamethasone.
- Trial name
- NCT02597062
- Testing
- Carfilzomib, Cyclophosphamide, Dexamethasone
- Where
- 9 sites in Canada
- Volunteers
- 76 people
- Sponsor
- Canadian Cancer Trials Group
Multiple Myeloma
Safety and Tolerability of BION-1301 in Adults With Relapsed or Refractory Multiple Myeloma (MM)
This is a Phase 1/2 study designed to evaluate the safety and tolerability of BION-1301 in adults with relapsed or refractory multiple myeloma whose disease has progressed after 3 or more prior systemic therapies.
- Trial name
- NCT03340883
- Testing
- BION-1301
- Where
- 7 sites in United States
- Volunteers
- 21 people
- Sponsor
- Chinook Therapeutics, Inc.
Multiple Myeloma
UARK 2010-35, A Study of Expanded Natural Killer Cell Therapy for Multiple Myeloma
The purpose of this study is to determine the therapeutic efficacy of the exp-NK cell therapy in research participants with relapsed high risk MM [defined as gene expression profile (GEP) 70 gene score ≥0.66 and/or metaphase…
- Trial name
- NK2010-35 (NCT01313897)
- Testing
- Bortezomib
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- University of Arkansas
Multiple Myeloma
CC-5013 With or Without Dexamethasone in Treating Patients With Primary Systemic Amyloidosis
RATIONALE: Drugs such as CC-5013 and dexamethasone may be effective in treating primary systemic amyloidosis. PURPOSE: This phase II trial is studying CC-5013 to see how well it works with or without dexamethasone in treating…
- Trial name
- NCT00091260
- Testing
- dexamethasone, lenalidomide
- Where
- United States
- Volunteers
- 82 people
- Sponsor
- Vaishali Sanchorawala
Multiple Myeloma
Bendamustine and Melphalan in Myeloma
Two high-dose chemotherapy regimens (melphalan alone versus the combination of melphalan and bendamustine) used for conditioning treatment before autologous stem cell transplantation will be compared in a 1:1 randomization in…
- Trial name
- BEB-2 (NCT03187223)
- Testing
- Melphalan, Bendamustine
- Where
- Switzerland
- Volunteers
- 120 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Multiple Myeloma
Study of Bendamustine Combined With Bortezomib for Patients With Relapsed/Refractory Multiple Myeloma
The primary objective of this study is to assess the safety and tolerability of bendamustine as combination therapy with bortezomib for patients with relapsed/refractory multiple myeloma (MM).
- Trial name
- NCT00920855
- Testing
- bendamustine, bortezomib
- Where
- 13 sites in United States
- Volunteers
- 40 people
- Sponsor
- Cephalon
Multiple Myeloma
Pegylated Liposomal Doxorubicin, Bortezomib, Dexamethasone and Lenalidomide for Relapsed/Refractory Multiple Myeloma
This is a phase II, multicenter, open label, nonrandomized study to evaluate the efficacy and safety of lenalidomide at a dose of 10 mg/dose in combination with bortezomib at 1.0 mg/m2/dose, pegylated liposomal doxorubicin (PLD)…
- Trial name
- NCT01160484
- Testing
- DVD-R
- Where
- 8 sites in United States
- Volunteers
- 40 people
- Sponsor
- Oncotherapeutics
Lung Cancer, Solid Tumor
Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)
The purpose of this study will be to evaluate the safety, tolerability, and pharmacological activity of pemigatinib in subjects with advanced malignancies.
- Conditions
- Lung Cancer, Solid Tumor, Gastric Cancer, Urothelial Cancer
- Trial name
- NCT02393248
- Testing
- Pemigatinib, Gemcitabine, Pembrolizumab
- Where
- 20 sites in United States, Denmark
- Volunteers
- 201 people
- Sponsor
- Incyte Corporation
Accelerated Phase Chronic Myelogenous Leukemia, Acute Undifferentiated Leukemia
Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer
This clinical trial studies the side effects and best dose of giving fludarabine and total-body irradiation (TBI) together followed by a donor stem cell transplant and cyclosporine and mycophenolate mofetil in treating human…
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Acute Undifferentiated Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission
- Trial name
- NCT00112593
- Testing
- fludarabine phosphate, total-body irradiation, peripheral blood stem cell transplantation
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Fred Hutchinson Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.